| Market Cap | 47.91M | P/E | - | EPS this Y | 36.00% | Ern Qtrly Grth | - |
| Income | -102.06M | Forward P/E | -0.71 | EPS next Y | 21.00% | 50D Avg Chg | -7.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -25.00% |
| Dividend | N/A | Price/Book | 0.28 | EPS next 5Y | - | 52W High Chg | -61.00% |
| Recommedations | 1.60 | Quick Ratio | 6.99 | Shares Outstanding | 61.61M | 52W Low Chg | 10.00% |
| Insider Own | 0.49% | ROA | -32.67% | Shares Float | 37.34M | Beta | 1.30 |
| Inst Own | 55.73% | ROE | -65.29% | Shares Shorted/Prior | 1.75M/1.21M | Price | 0.88 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 259,572 | Target Price | 7.00 |
| Oper. Margin | - | Earnings Date | May 9 | Volume | 119,590 | Change | -1.46% |
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
| Canaccord Genuity | Buy | Mar 5, 24 |
| Raymond James | Outperform | Nov 14, 23 |
| Chardan Capital | Buy | Aug 8, 23 |
| Raymond James | Outperform | May 12, 23 |
| Chardan Capital | Buy | Dec 15, 22 |
| Guggenheim | Buy | Nov 11, 22 |
| Citigroup | Buy | Nov 11, 22 |
| Canaccord Genuity | Buy | Nov 8, 22 |
| Citigroup | Buy | May 17, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kapadia Sandip | Director Director | Dec 01 | Sell | 1.1929 | 5,000 | 5,964 | 12/02/22 | |
| Fotopoulos Alexandros | Chief Technical Offi.. Chief Technical Officer | Nov 22 | Option | 0 | 12,500 | 23,965 | 11/25/22 | |
| Fotopoulos Alexandros | Chief Technical Offi.. Chief Technical Officer | Nov 22 | Sell | 1.33 | 3,720 | 4,948 | 20,245 | 11/25/22 |
| ORBIMED ADVISORS LLC | 10% Owner 10% Owner | May 03 | Buy | 1.94 | 525,000 | 1,018,500 | 6,841,423 | 05/05/22 |
| ORBIMED ADVISORS LLC | 10% Owner 10% Owner | Jan 20 | Buy | 5.00 | 50,800 | 254,000 | 6,316,423 | 05/05/22 |
| Goldsmith Bruce A | CEO and President CEO and President | Mar 21 | Buy | 3.15 | 10,000 | 31,500 | 15,983 | 03/23/22 |
| ORBIMED ADVISORS LLC | 10% Owner 10% Owner | Jan 14 | Buy | 5.39 | 168,300 | 907,137 | 6,265,623 | 01/20/22 |
| ORBIMED ADVISORS LLC | 10% Owner 10% Owner | Jan 11 | Buy | 5.57 | 150,000 | 835,500 | 6,097,323 | 01/13/22 |